List of Excipients in Branded Drug EQUATE NICOTINE

Generic Drugs Containing EQUATE NICOTINE

Company	Ingredient	NDC	Excipient
Wal-Mart Stores Inc	nicotine polacrilex	49035-029	ACESULFAME POTASSIUM
Wal-Mart Stores Inc	nicotine polacrilex	49035-029	CALCIUM CARBONATE
Wal-Mart Stores Inc	nicotine polacrilex	49035-029	CARNAUBA WAX
Wal-Mart Stores Inc	nicotine polacrilex	49035-029	POLACRILIN

What are the Most Frequently-Used Excipients in EQUATE NICOTINE?

# Of NDCs	Excipient
7	ACACIA
23	ACESULFAME POTASSIUM
2	ASPARTAME
2	BENZALDEHYDE

Equate Nicotine Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

Equate Nicotine is a Walmart private-label nicotine-replacement therapy portfolio, not a single pharmaceutical product. Its commercial scope generally includes nicotine polacrilex gum, lozenges, and transdermal patches. The active ingredient is off-patent and widely available. Competitive value therefore depends on excipient performance, taste, release control, manufacturing cost, packaging, regulatory execution, and retail distribution rather than composition-of-matter exclusivity.

The strongest opportunities are in nicotine gum and lozenges, where excipients directly affect nicotine release, mouthfeel, irritation, stability, and consumer adherence. Patch opportunities are more formulation- and manufacturing-intensive, with greater potential for technical differentiation but higher development barriers.

What products are sold under the Equate Nicotine brand?

Equate-branded nicotine-replacement products are typically sold in three dosage forms:

Dosage form	Active ingredient	Main excipient functions	Commercial position
Nicotine gum	Nicotine polacrilex	Chewability, buffering, sweetness, flavor, controlled release	Low-cost alternative to branded gum
Nicotine lozenge	Nicotine polacrilex or nicotine-containing compressed matrix	Dissolution, taste masking, saliva compatibility, buffering	Convenience and discreet use
Nicotine patch	Nicotine	Adhesion, skin permeation, reservoir or matrix control, stability	Once-daily dosing and adherence

The specific Equate product, strength, package count, manufacturer, NDC, and label instructions vary by stock-keeping unit. Product-level analysis must distinguish the 2 mg and 4 mg strengths and separate gum, lozenge, and patch formulations. DailyMed and product labeling are the primary sources for identifying the active ingredient, inactive ingredients, manufacturer, and dosage instructions.[1]

What excipients are used in nicotine gum and lozenges?

Nicotine gum and lozenges use excipients that control three commercial variables: nicotine liberation, sensory acceptability, and product robustness.

Nicotine gum excipient strategy

Nicotine gum commonly uses a gum base containing polymers, waxes, elastomers, fillers, softeners, and plasticizers. The gum base determines the force required to chew and the rate at which nicotine is released into saliva.

Important excipient categories include:

• Gum base polymers for chewability and controlled mastication.
• Buffering agents such as carbonate or bicarbonate systems to raise salivary pH and improve nicotine absorption.
• Sweeteners, including sugar alcohols, to improve taste and reduce dental concerns.
• Flavor systems, often mint or fruit-mint profiles, to reduce nicotine bitterness.
• Humectants and softeners to control texture during shelf life.
• Antioxidants and stabilizers to limit nicotine degradation.
• Coatings or outer layers to manage initial flavor release and moisture transfer.

The most valuable formulation parameter is not simply total nicotine content. It is the amount of nicotine released during the recommended chew-and-park method. A formulation that releases nicotine too quickly may increase throat irritation, hiccups, nausea, or poor tolerability. A formulation that releases too slowly may reduce perceived effectiveness and repeat purchase.

Nicotine lozenge excipient strategy

Lozenges provide more direct control over dissolution than gum. Key variables include tablet hardness, porosity, wetting, saliva-triggered disintegration, flavor persistence, and nicotine release.

Common excipient functions include:

• Compression fillers that provide tablet mass and mechanical strength.
• Binders that control friability and dissolution.
• Disintegrants that regulate tablet breakup.
• Lubricants that support tableting without excessively slowing dissolution.
• Sweeteners and polyols for taste and mouthfeel.
• Buffers that affect nicotine ionization and absorption.
• Flavoring agents that mask bitterness and burning.
• Film or sugar coatings that improve handling and consumer acceptance.

A commercial opportunity exists for a lozenge that reduces the initial nicotine burn while preserving release performance. Another opportunity is a smaller, lower-residue dosage form with reduced chalkiness and shorter dissolution time.

Excipient risks in oral nicotine products

Nicotine products have narrow sensory tolerance. Excessive buffering can increase irritation. High levels of hydrophobic lubricants can delay dissolution. Some flavor systems can interact with nicotine or produce stability problems. Polyols may cause gastrointestinal discomfort at higher intake levels, while sugar-containing systems may face consumer resistance among users concerned about dental health.

Excipient selection must be assessed against:

• Nicotine assay and degradation products.
• Dissolution or release profile.
• Moisture uptake.
• Tablet hardness and gum texture.
• Flavor stability.
• Packaging compatibility.
• Extractables and leachables.
• Microbial limits.
• Maximum daily exposure to each excipient.

FDA’s Inactive Ingredient Database can support precedent review, but prior use in another dosage form does not establish automatic suitability for a nicotine product or a particular exposure level.[2]

What excipients are used in nicotine patches?

Nicotine patches use a pressure-sensitive adhesive, a backing layer, a release liner, and either a drug-in-adhesive matrix or another controlled-release configuration.

The commercial performance of a patch depends on:

• Adhesive contact with skin.
• Nicotine loading and uniformity.
• Permeation through the skin.
• Patch wear time.
• Resistance to edge lift and sweating.
• Skin irritation and sensitization.
• Protection from oxygen, moisture, and light.
• Peel force and residue after removal.

A patch formulation can use acrylic, silicone, or rubber-based adhesive technologies. Each system creates different tradeoffs in adhesion, drug compatibility, skin tolerability, and manufacturing cost.

The most defensible patch opportunity is a performance improvement rather than a new active ingredient. Examples include improved adhesion under perspiration, reduced skin residue, better low-temperature performance, or a thinner construction that maintains dose delivery. These improvements may support formulation, device, process, or packaging claims, although patentability depends on the specific technical disclosure and prior art.

What patents protect Equate Nicotine?

No single patent can be assigned to the Equate Nicotine brand without identifying the exact product, NDC, sponsor, and manufacturing entity. The nicotine active ingredient is long off-patent. Relevant protection, where it exists, is more likely to concern formulation architecture, delivery systems, manufacturing processes, packaging, or specific methods of use.

IP category	Relevance to Equate Nicotine	Expected legal significance
Nicotine composition-of-matter patents	Minimal for ordinary nicotine products	Expired or commercially irrelevant
Nicotine polacrilex composition	Potentially relevant to resin or complexation design	Usually limited by prior art and historical use
Gum formulation patents	Release, texture, buffering, flavor, and base composition	May affect branded or differentiated products
Lozenge formulation patents	Dissolution, taste masking, compression, and release	Potentially relevant to new products
Patch patents	Adhesive, matrix, permeation, multilayer construction	Higher technical and litigation relevance
Manufacturing patents	Mixing, coating, drying, lamination, and process controls	Relevant where the process is difficult to design around
Packaging patents	Moisture control, child resistance, and unit-dose systems	Commercially useful but generally narrower
Method-of-use patents	Dosing schedules or cessation regimens	Limited relevance for standard OTC labeling

A public brand name does not establish patent ownership. Private-label products may be manufactured by a third party under contract, and the applicable IP may be owned by the manufacturer, a formulation developer, or a separate licensor.

What is the Orange Book status of Equate Nicotine?

Equate Nicotine should not be treated as an ordinary branded prescription product with a conventional Orange Book patent listing. OTC nicotine-replacement products may be marketed under FDA OTC pathways or under approved applications depending on the product and regulatory history. The Orange Book does not function as a complete patent registry for every private-label OTC nicotine product.[3]

The absence of an obvious Orange Book listing would not establish that the product has no relevant intellectual-property constraints. It would indicate only that patent and exclusivity analysis must examine:

• The applicable FDA regulatory pathway.
• Any referenced or abbreviated application.
• The product’s NDC and label history.
• Manufacturer-owned patents.
• Licensing arrangements.
• Patent litigation databases.
• FDA patent and exclusivity records where applicable.

When does Equate Nicotine lose exclusivity?

Equate Nicotine does not have a single exclusivity-loss date. The active ingredient and basic nicotine-replacement concept are already genericized. Commercial exclusivity is instead determined by retail placement, price, supply arrangements, formulation know-how, and any surviving product or process rights.

For standard nicotine gum, lozenge, and patch products, generic entry is not generally blocked by a composition-of-matter patent. The principal barriers are:

1. Regulatory compliance.
2. Manufacturing scale.
3. Taste and texture performance.
4. Stability and packaging.
5. Retail qualification.
6. Contract manufacturing capacity.
7. Brand recognition and shelf placement.

The relevant commercial question is therefore whether a challenger can produce a product with equivalent nicotine delivery and acceptable sensory performance at a lower delivered cost.

Are Paragraph IV challenges relevant to Equate Nicotine?

Paragraph IV litigation is usually associated with an ANDA applicant asserting that listed patents are invalid, unenforceable, or not infringed. Its relevance to Equate Nicotine depends on whether the specific product is tied to an approved application with Orange Book-listed patents.

For a conventional OTC nicotine product marketed under an OTC monograph framework, a classic Paragraph IV launch dispute may not arise. A product marketed through an approved NDA or another application pathway could present a different analysis. The product label and regulatory record must be matched to the applicable application before assessing Paragraph IV risk.[3][4]

The generic launch risk for oral nicotine products is generally higher than for transdermal patches because oral products are easier to manufacture and have fewer device and adhesive-performance variables. Patches can present more complex equivalence and quality-control requirements.

What patent litigation affects Equate Nicotine?

No Equate-specific litigation conclusion can be drawn from the brand name alone. The appropriate litigation screen should identify:

• The legal manufacturer.
• The NDA, ANDA, or OTC regulatory basis.
• Patents owned by the manufacturer or licensor.
• Patent cases involving nicotine gum, lozenges, or patches.
• Settlements that restrict supply, formulation, or launch timing.
• Trade-secret claims involving manufacturing or coating processes.

Litigation risk is more likely to arise from formulation and delivery technology than from nicotine itself. For patches, adhesive and transdermal delivery patents can create the most material exposure. For gum and lozenges, claims may focus on nicotine release, buffering, taste masking, or dosage-form architecture.

How strong is the Equate Nicotine patent estate?

The likely brand-level patent estate is weak to moderate because Equate is a private-label retail brand built around an established active ingredient and mature dosage forms. The potentially stronger IP is held at the supplier or technology level, particularly for:

• Controlled-release patch matrices.
• Skin-compatible adhesive systems.
• High-loading nicotine adhesives.
• Taste-masked lozenges.
• Specialized nicotine-resin complexes.
• Moisture-resistant unit-dose packaging.
• Manufacturing processes that improve uniformity or yield.

Patent strength depends on claim breadth, prosecution history, prior-art density, design-around options, remaining term, and whether the patent is practiced by the commercial product. A narrow formulation claim may have practical value if the manufacturing process is difficult to modify, even when the underlying patent estate is not broad.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can target Equate-type products through technical improvements that reduce cost or increase consumer adherence.

Oral dosage-form opportunities

The highest-probability opportunities include:

• Low-bitterness flavor systems.
• Buffer systems with less throat irritation.
• Direct-compression excipient platforms for robust lozenges.
• Sugar-free systems with improved mouthfeel.
• Gum bases with predictable nicotine release.
• Moisture-barrier coatings.
• Polyol systems with lower gastrointestinal impact.
• Stabilizer packages that extend shelf life.
• Excipient premixes that simplify manufacturing validation.

A supplier with a prequalified excipient blend can reduce development time for private-label manufacturers. The commercial value increases when the blend improves several attributes at once, such as taste, hardness, dissolution, and stability.

Patch opportunities

Patch-focused suppliers can target:

• Low-irritation pressure-sensitive adhesives.
• Adhesives with improved sweat resistance.
• Drug-in-adhesive systems with consistent nicotine distribution.
• Permeation-control excipients.
• Flexible backing films.
• Low-residue removal systems.
• High-barrier pouch materials.
• Continuous coating technologies that reduce waste.

Patch development has a higher qualification burden. A supplier must demonstrate adhesive performance, nicotine compatibility, skin tolerability, dose uniformity, and stability across the intended shelf life.

How does Equate Nicotine compare with Nicorette and other competitors?

Factor	Equate Nicotine	Nicorette	Store-brand generics
Primary advantage	Price and Walmart distribution	Brand recognition and product breadth	Price competition
Patent value	Usually limited at brand level	May include formulation or delivery rights, depending on product	Usually limited
Excipient differentiation	Taste, texture, release, packaging	Product experience and established formulations	Cost and acceptable equivalence
Regulatory risk	Product-specific OTC or application pathway	Established branded regulatory history	Product-specific
Retail leverage	Strong private-label shelf access	Broad pharmacy and retail distribution	Variable
Commercial vulnerability	Supplier concentration and price pressure	Premium pricing and generic substitution	Low differentiation

Equate can gain share when consumers trade down from branded nicotine-replacement products. Its main constraints are private-label pricing pressure, limited consumer attachment to the brand, and the need to maintain consistent sensory quality across suppliers.

What is the FDA regulatory status of Equate Nicotine?

Nicotine gum, lozenges, and patches are FDA-regulated drug products. The applicable pathway depends on the specific product and its regulatory history. Product labels must comply with FDA requirements for active ingredients, directions, warnings, contraindications, and Drug Facts presentation.[1][5]

Excipient changes can trigger regulatory work even when the active ingredient and strength remain unchanged. The impact depends on whether the change affects:

• Nicotine release.
• Bioavailability.
• Stability.
• Product performance.
• Label claims.
• Manufacturing controls.
• Product equivalence.

For OTC products, a seemingly minor change in flavor, buffer, coating, or adhesive can require comparative testing and updated quality documentation.

What geographic coverage and manufacturing barriers exist?

The Equate brand is primarily associated with U.S. retail distribution, but nicotine-replacement products are sold globally under different regulatory systems. A formulation designed for the U.S. market may require separate assessment for Canada, the European Union, the United Kingdom, Australia, and other jurisdictions.

Manufacturing barriers include:

• Specialized gum-base processing.
• Controlled nicotine handling.
• Low-dose content uniformity.
• Tablet compression and coating.
• Transdermal coating and lamination.
• High-barrier packaging.
• Stability testing under multiple climatic conditions.
• Supplier qualification for flavors, adhesives, and polymers.
• Child-resistant packaging requirements.

The strongest manufacturing moat is usually found in transdermal patches and complex gum-base systems. Standard lozenges have lower technical barriers but face intense price competition.

What revenue exposure does Equate Nicotine create?

Equate Nicotine revenue exposure is linked to nicotine-replacement demand, Walmart traffic, smoking-cessation behavior, tobacco regulation, and substitution among branded and generic products. Revenue risk is concentrated in:

• Retail price reductions.
• Out-of-stock events.
• Contract-manufacturer changes.
• Product recalls.
• Sensory defects that reduce repeat use.
• Competitive private-label launches.
• Shifts toward vaping or prescription cessation therapies.
• Changes in smoking prevalence.

Excipient changes that improve taste and adherence can have disproportionate commercial impact because nicotine-replacement therapy depends on repeated use over a cessation period. A small reduction in irritation or bitterness may improve continuation without requiring a new active ingredient or new indication.

Key Takeaways

• Equate Nicotine is a private-label nicotine-replacement portfolio, not a single patented drug.
• The active ingredient is mature and generally offers little composition-of-matter protection.
• Excipient value is highest in nicotine gum and lozenges, where taste, buffering, texture, and release control drive adherence.
• Patch opportunities are technically stronger but require adhesive, permeation, stability, and manufacturing expertise.
• Orange Book and Paragraph IV analysis is product-specific and cannot be inferred from the Equate brand name.
• The most attractive commercial opportunities are low-irritation flavors, improved buffers, sugar-free mouthfeel systems, controlled-release gum bases, skin-compatible adhesives, and high-barrier packaging.
• Manufacturing know-how and supplier relationships may create more practical protection than broad patent claims.

FAQs

Can a new excipient create patent protection for an Equate nicotine product?

Yes, but only if the formulation or use involving the excipient satisfies patentability requirements. A routine substitution of one flavor, filler, or lubricant for another is vulnerable to obviousness challenges. Stronger claims require an unexpected performance result, a non-obvious combination, or a technically difficult manufacturing advantage.

Are nicotine polacrilex products biologics?

No. Nicotine polacrilex gum and lozenges are small-molecule drug products involving a nicotine-resin complex. They do not create biosimilar exposure in the way monoclonal antibodies, recombinant proteins, or other biologics do.

Which Equate nicotine dosage form has the highest formulation risk?

Transdermal patches generally have the highest formulation risk because adhesion, drug distribution, skin permeation, irritation, packaging, and dose delivery must remain consistent throughout shelf life.

Can a flavor change trigger new FDA regulatory work?

Yes. A flavor change can affect nicotine release, stability, consumer tolerability, impurity formation, and labeling. The regulatory burden depends on the product pathway and the demonstrated effect of the change.

What is the most defensible commercial position for a new nicotine excipient platform?

A platform that improves taste, release control, stability, and manufacturing efficiency at the same time has the strongest commercial position. A single-attribute improvement is easier for competitors to copy and harder to justify at a premium price.

References

1. U.S. National Library of Medicine. (n.d.). DailyMed: Current medication information. https://dailymed.nlm.nih.gov/dailymed/
2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data
4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions and Paragraph IV certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
5. U.S. Food and Drug Administration. (n.d.). Over-the-counter drug review and monograph system. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs